Amedeo Smart

Free Medical Literature Service



Bladder Cancer

  Free Subscription


1 Biochem Biophys Res Commun
1 Cancer Biomark
1 Cancers (Basel)
1 Cell
2 Int J Oncol
1 Int Urol Nephrol
1 J Comput Assist Tomogr
1 J Immunother Cancer
1 Nat Rev Urol
1 Oncol Lett
1 Oncol Rep
1 Trials
1 World J Urol

    Biochem Biophys Res Commun

  1. TUO Z, Zhang J, Xue W
    LncRNA TP73-AS1 predicts the prognosis of bladder cancer patients and functions as a suppressor for bladder cancer by EMT pathway.
    Biochem Biophys Res Commun. 2018 Apr 3. pii: S0006-291X(18)30773.
    >> Share

    Cancer Biomark

  2. ZHU Z, Xu L, Wan Y, Zhou J, et al
    Inhibition of E-cadherin expression by lnc-RNA H19 to facilitate bladder cancer metastasis.
    Cancer Biomark. 2018 Mar 19. pii: CBM170998. doi: 10.3233/CBM-170998.
    >> Share

    Cancers (Basel)

    Bladder Cancer: New Insights into Its Molecular Pathology.
    Cancers (Basel). 2018;10.
    >> Share


  4. LEE SH, Hu W, Matulay JT, Silva MV, et al
    Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.
    Cell. 2018;173:515-528.
    >> Share

    Int J Oncol

  5. LIU M, Chen Y, Huang B, Mao S, et al
    Tumor-suppressing effects of microRNA-612 in bladder cancer cells by targeting malic enzyme 1 expression.
    Int J Oncol. 2018 Mar 29. doi: 10.3892/ijo.2018.4342.
    >> Share

  6. LI C, Liu J, Zhang Q, Cui K, et al
    Upregulation of Ecadherin expression mediated by a novel dsRNA suppresses the growth and metastasis of bladder cancer cells by inhibiting beta-catenin/TCF target genes.
    Int J Oncol. 2018 Mar 29. doi: 10.3892/ijo.2018.4346.
    >> Share

    Int Urol Nephrol

  7. BATURA D, Hashemzehi T, Colemeadow J
    A care bundle to improve perioperative mitomycin use in non-muscle-invasive bladder cancer.
    Int Urol Nephrol. 2018 Apr 2. pii: 10.1007/s11255-018-1863.
    >> Share

    J Comput Assist Tomogr

  8. MAMMEN S, Krishna S, Quon M, Shabana WM, et al
    Diagnostic Accuracy of Qualitative and Quantitative Computed Tomography Analysis for Diagnosis of Pathological Grade and Stage in Upper Tract Urothelial Cell Carcinoma.
    J Comput Assist Tomogr. 2018;42:204-210.
    >> Share

    J Immunother Cancer

  9. SWEIS RF, Zha Y, Pass L, Heiss B, et al
    Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.
    J Immunother Cancer. 2018;6:24.
    >> Share

    Nat Rev Urol

  10. THOMA C
    Bladder cancer: Neuroendocrine disease genomics.
    Nat Rev Urol. 2018 Apr 5. pii: nrurol.2018.42. doi: 10.1038/nrurol.2018.
    >> Share

    Oncol Lett

  11. GAO JM, Huang LZ, Huang ZG, He RQ, et al
    Clinical value and potential pathways of miR-183-5p in bladder cancer: A study based on miRNA-seq data and bioinformatics analysis.
    Oncol Lett. 2018;15:5056-5070.
    >> Share

    Oncol Rep

  12. XIAO J, Niu S, Zhu J, Lv L, et al
    miR223p enhances multichemoresistance by targeting NET1 in bladder cancer cells.
    Oncol Rep. 2018 Apr 4. doi: 10.3892/or.2018.6355.
    >> Share


  13. CRABB S, Danson SJ, Catto JWF, McDowell C, et al
    SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial.
    Trials. 2018;19:216.
    >> Share

    World J Urol

  14. LIANG Z, Xin R, Yu Y, Wang R, et al
    Diagnostic value of urinary survivin as a biomarker for bladder cancer: a systematic review and meta-analysis of published studies.
    World J Urol. 2018 Apr 2. pii: 10.1007/s00345-018-2285.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016